Rethinking Reimbursement: France’s Article 51 as a Model for Real-World Innovation In 2018, France introduced a powerful tool to reshape its health system from within: Article 51 of the Loi de Financement de la Sécurité …

In the two decades since the arrival of robotic-assisted surgery (RAS), clinical teams across urology, colorectal, gynaecological and orthopaedic domains have embraced its ergonomic advantages, precision tooling and potential for same-day recovery. …

Melanoma has seen an extraordinary therapeutic revolution over the past decade, with immune checkpoint inhibitors (e.g. nivolumab, pembrolizumab, ipilimumab) and BRAF/MEK inhibitors (e.g. dabrafenib/trametinib, vemurafenib/cobimetinib) substantially improving survival. However, the challenge for …

The National Institute for Health and Care Excellence (NICE) has recently updated its Real-World Evidence (RWE) Framework, formally recognising qualitative research as an important contributor to health technology assessment (HTA) in England. This update offers …

In January 2024, the Dutch National Health Care Institute (Zorginstituut Nederland) published a comprehensive update to its Guideline for Economic Evaluations in Healthcare, the first since 2016. More than just a procedural refresh, this …

The reimbursement of orphan medicinal products (OMPs) for rare diseases remains one of the most complex challenges in European healthcare policy. These therapies frequently launch with limited clinical evidence, small target populations and high …

The UK is entering a bold new chapter in how innovative medicines and diagnostics reach patients, and it’s one that could re-define the global standard. With a series of strategic reforms unveiled …

How do we measure How healthy’ someone really is?  And how do we turn that into numbers that help shape health policy, pricing decisions and even drug approvals? That’s where the EQ-5D-5L comes in. Created …